本期 13F-HR 中的全部持仓，以及相对上季度的变化。
13F 持仓，最新季度
来源SEC EDGAR13F-HR
Remedium Capital Partners, LLC (CIK 2104501) reported $451.6M across 6 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: ORKA ($149.0M, 32.99%), SYRE ($130.0M, 28.78%), APGE ($77.9M, 17.24%), DMRA ($53.2M, 11.78%), JBIO ($35.1M, 7.76%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ORKA | Oruka Therapeutics Inc | $149.0M | 32.99% | 1.6M | Hold |
| 2 | SYRE | Spyre Therapeutics Inc | $130.0M | 28.78% | 1.5M | Added |
| 3 | APGE | Apogee Therapeutics Inc | $77.9M | 17.24% | 586,691 | Added |
| 4 | DMRA | Damora Therapeutics Inc | $53.2M | 11.78% | 2.0M | Hold |
| 5 | JBIO | Jade Biosciences Inc | $35.1M | 7.76% | 1.6M | Hold |
| 6 | CBIO | Crescent Biopharma Inc | $6.5M | 1.44% | 361,250 | New |
| 7 | CBIOXXXX | Crescent Biopharma Inc | $0 | 0.00% | 0 | Exited |
来源：SEC 13F 申报文件 · 截至 2026-06-30